Tse Archie N, Sheikh Tahir N, Alan Ho, Chou Ting-Chao, Schwartz Gary K
Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Mol Pharmacol. 2009 Jan;75(1):124-33. doi: 10.1124/mol.108.050807. Epub 2008 Sep 26.
The G(2)/M cell cycle checkpoint is regulated by a multitude of signaling pathways after genotoxic stress. Herein, we report that treatment with the 90-kDa heat shock protein (Hsp90) molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) selectively abrogates the G(2)/M checkpoint induced by 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, in p53-null compared with p53-intact HCT116 colon cancer cells. The basis for this selectivity can be explained in part by the lack of p21 induction in p53-null cells. In accord with published results, we could show that treatment with 17AAG resulted in depletion of Chk1, a known Hsp90 client protein. In addition, we observed a time- and dose-dependent decrease in Wee1 kinase level, a negative regulator of mitosis, after 17AAG treatment in gastrointestinal cancer cells. Depletion of Wee1 protein preceded mitotic entry induced by 17AAG, and this decrease could be partially rescued by cotreatment with a proteasome inhibitor. Coimmunoprecipitation experiments showed that Hsp90 and Wee1 interacted in whole cells, and 17AAG treatment decreased the degradative half-life of Wee1, indicating that Wee1 is another Hsp90 client in mammalian cells. Knockdown of Chk1 and Wee1 by short interfering RNA each resulted in abrogation of the G(2)/M checkpoint induced by SN-38. The combination of SN-38 and 17AAG was shown to be synergistic in p53-null but not in parental HCT116 cells by median effect/combination index analysis. Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1.
基因毒性应激后,G(2)/M细胞周期检查点受多种信号通路调控。在此,我们报告,与p53完整的HCT116结肠癌细胞相比,用90-kDa热休克蛋白(Hsp90)分子伴侣抑制剂17-烯丙基氨基-17-去甲氧基格尔德霉素(17AAG)处理可选择性消除由伊立替康的活性代谢物7-乙基-10-羟基喜树碱(SN-38)诱导的p53缺失细胞中的G(2)/M检查点。这种选择性的基础部分可通过p53缺失细胞中缺乏p21诱导来解释。与已发表的结果一致,我们可以证明用17AAG处理会导致已知的Hsp90客户蛋白Chk1的消耗。此外,我们观察到在胃肠道癌细胞中用17AAG处理后,有丝分裂的负调节因子Wee1激酶水平呈时间和剂量依赖性下降。在17AAG诱导有丝分裂进入之前,Wee1蛋白就已耗尽,并且这种下降可通过与蛋白酶体抑制剂共同处理而部分挽救。免疫共沉淀实验表明,Hsp90和Wee1在全细胞中相互作用,17AAG处理降低了Wee1的降解半衰期,表明Wee1是哺乳动物细胞中的另一种Hsp90客户蛋白。通过短干扰RNA敲低Chk1和Wee1均导致SN-38诱导的G(2)/M检查点被消除。通过中位效应/联合指数分析表明,SN-38和17AAG的组合在p53缺失细胞中具有协同作用,但在亲本HCT116细胞中则不然。综上所述,17AAG通过下调两种关键的检查点激酶Chk1和Wee1,特异性抑制p53缺陷细胞中的G(2)/M检查点。